Latest Headlines

31. Finding A New Drug Target To Treat Frontotemporal Lobar Degeneration 4/7/2025

    Frontotemporal Lobar Degeneration (FTLD) is a neurodegenerative disease affecting the frontal and temporal lobes that regulate higher cognitive brain functions such as personality, behavior, and language.

32. ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases 4/6/2025

    ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.

33. Plex Research Partners With Ginkgo Bioworks On Artificial Intelligence (AI)-Powered Drug Discovery To Identify Novel Disease Mechanisms And Pathways 4/3/2025

    Plex Research, a biotechnology company using autonomous artificial intelligence (AI) to aid in drug discovery, today announced that it is partnering with Ginkgo Datapoints, a service of Ginkgo Bioworks, to use the Plex AI Platform to deepen the understanding of compound treatment mechanisms of action, potentially revealing new therapeutic applications, based on a large perturbation response profiling dataset.

34. IRBM Expands Functional Genomics Platform To Strengthen Early Drug Discovery 4/3/2025

    IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, and generation of disease-relevant cellular models.

35. Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery 4/2/2025

    Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle.

36. MultiOmic Health And Alloy Therapeutics Collaborate To Discover And Develop Renal Tissue-Targeting Drugs 4/2/2025

    MultiOmic Health Limited (“MOH”), an artificial intelligence (AI)-enabled precision medicine discovery company focused on chronic multifactorial diseases, and Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced they have signed a Memorandum of Understanding to jointly discover and develop first-in-class renal tissue-targeting drugs.

37. Certara Expands The Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities 4/1/2025

    Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK models describe and predict the behavior of drugs in different body tissues.

38. Kanvas Bio Publishes New Research On Its Novel Spectral Imaging Platform, A Transformative Tool For Microbiome Drug Discovery And Development 4/1/2025

    Kanvas Biosciences, a full-stack spatial biology company, today announced new research outlining the capabilities of its High-Phylogenetic-Resolution Spatial Mapping (HiPR-Map) Platform, a state-of-the-art spectral imaging technology that enables precise enumeration and spatial localization of microbial cells within complex communities.

39. Flagship Pioneering Announces Agreement Between Pioneering Medicines And Pfizer To Discover Potential Novel, Selective Inhibitors For Autoimmune Disease 4/1/2025

    Flagship Pioneering, the bioplatform innovation company, today announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

40. Ono Enters Into Drug Discovery Collaboration Agreement With Reborna Biosciences To Generate RNA-Targeting Novel Small Molecule In The Central Nervous System Area 3/31/2025

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that it has entered into a drug discovery collaboration agreement with Reborna Biosciences, Inc. (Headquarters: Kanagawa, Japan; Representative Director: Koji Fuji; “Reborna”) to generate ribonucleic acid (RNA)-targeting novel small molecule in the field of central nervous system.